n-Propyl 5,8,11,14,17-eicosapentaenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: n-Propyl 5,8,11,14,17-eicosapentaenoate
• 英文别名: propyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
• 化学式: C₂₃H₃₆O₂
• 分子量: 344.5
• InChiKey: FRBIUVCVJGQJKO-AAQCHOMXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  25
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
  申请人：Alapati Mohan Murali

  公开号：US20170129870A1

  公开（公告）日：2017-05-11

  The compositions and compounds of Formula I which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder, general anxiety disorder, urinary incontinence, painful peripheral neuropathy, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain associated with osteoarthritis and chronic lower back pain.

  Formula I的组成和化合物包括度洛西汀盐或其多晶形、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射用药物组合物。这些组合物可用于治疗重性抑郁障碍、广泛性焦虑障碍、尿失禁、疼痛性周围神经病、糖尿病性神经病、纤维肌痛和与骨关节炎和慢性腰背痛相关的慢性肌肉骨骼疼痛。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
  申请人：Kandula Mahesh

  公开号：US20160115115A1

  公开（公告）日：2016-04-28

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of salts of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES
  申请人：Alapati Mohan Murali

  公开号：US20170073345A1

  公开（公告）日：2017-03-16

  The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compounds and compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
• US9206111B1
  申请人：——

  公开号：US9206111B1

  公开（公告）日：2015-12-08
• US9725404B2
  申请人：——

  公开号：US9725404B2

  公开（公告）日：2017-08-08